Please note, this OEL/ADE monograph also applies to quetiapine fumarate (CAS RN 111974-72-2). Quetiapine is indicated to treat bipolar disorder, major depressive disorder, manic bipolar disorder, and schizophrenia. The mechanism of action of quetiapine fumarate is unknown, although, it is believed that efficacy in schizophrenia and its mood stabilization properties are due to the combined antagonism of D(2) and 5HT(2) receptors, and the efficacy in major depression may be partially explained by norepinephrine antagonism.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Quetiapine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.